Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has approved Keytruda Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the… read more.
Cervical cancer, the fourth most common cancer type in women, causes approximately 350,000 deaths each year, mainly in middle- and low-income countries. Human papillomavirus (HPV) infection is known… read more.
Researchers at Karolinska Institutet in Sweden, in collaboration with the University of Innsbruck in Austria, have developed a simpler and more effective screening method for cervical cancer than… read more.
People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer are at lower risk for long-term side effects, according to a new study… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking… read more.
Seagen Inc. and Genmab A/S announced that the Phase III innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line… read more.
At-home high-risk human papillomavirus (hrHPV) sampling kits can help increase cervical cancer screening among under-screened women from low-income backgrounds, according to findings from a US-based clinical trial published… read more.
Tobacco use is the leading preventable cause of death in the U.S., accounting for about 1 in 5 deaths each year. It is also a risk factor for… read more.
Merck Inc., announced that the FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic… read more.
Merck Inc., announced that the pivotal Phase III KEYNOTE-826 trial investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with… read more.
Article written by Bruce Sylvester. In locally advanced cervical cancer, use of adjuvant chemotherapy after standard chemoradiation does not improve mortality outcomes. Researchers reported this finding on June… read more.
Interview and article by Christine Clark Cervical cancer accounts for about 850 cancer deaths in the UK every year – more than two every day – and yet… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
